abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 08월 28일 16시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

Hammerhead ribozyme and DNAzyme that specifically cleaves leukemogenic TEL–AML1 mRNA

등록일
2008년 8월 11일 17시 15분 22초
접수번호
0686
발표코드
33P195포 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
목 <발표Ⅰ>
발표형식
포스터
발표분야
생명화학
저자 및
공동저자
최보라, 김동은
건국대학교 생명공학과, Korea
In order to develop the oligonucleotides to abolish an expression of TEL–AML1 chimeric RNA, which is a genetic aberration that causes the acute lymphoblastic leukemia (ALL), hammerhead ribozymes and deoxyoligoribozymes that can specifically cleave TEL–AML1 fusion RNA were designed. Constructs of the deoxyribozyme with an asymmetric substrate binding arm (Dz26) and the hammerhead ribozyme with a 4 nt-bulged substrate binding arm in the stem III (buRz28) were able to cleave TEL–AML1chimeric RNA specifically at sites close to the junction in vitro, without cleaving the normal TEL and AML1 RNA. Single-turnover kinetic analysis under enzyme-excess condition revealed that the buRz28 is superior to the Dz26 in terms of substrate binding and RNA-cleavage. Designed DNAzyme and hammerhead ribozyme were transferred into the cells that express TEL–AML1gene. Expression of TEL–AML1gene was efficiently inhibited with both DNAzyme and ribozyme. In conjunction with current progress in a gene-delivery technology, the designed oligonucleotides that specifically cleave the TEL–AML1chimeric mRNA are hoped to be applicable for the treatment of ALL in vivo. This research was supported by the KOSEF grant (R01-2006-000-20617-0) funded by the korean government.

상단으로